OGN 9.68 ▼ -1.53% Live Trading Data - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Organon & Co.

    NYSE: OGN · Real-Time Price · USD
    9.68
    -0.15 (-1.53%)
    At close: Sep 04, 2025, 3:59 PM
    9.72
    0.41%
    Pre-market: Sep 05, 2025, 09:05 AM EDT
    -1.53%
    Bid 9.58
    Market Cap 2.52B
    Revenue (ttm) 4.69B
    Net Income (ttm) 555.14M
    EPS (ttm) 2.69
    PE Ratio (ttm) 3.6
    Forward PE 2.43
    Analyst Hold
    Ask 9.8
    Volume 2,549,049
    Avg. Volume (20D) 4,102,472
    Open 9.82
    Previous Close 9.83
    Day's Range 9.61 - 9.94
    52-Week Range 8.01 - 22.42
    Beta 0.56

    About OGN

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol OGN
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for OGN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Organon & Co. is scheduled to release its earnings on Oct 30, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription
    1 month ago
    -13.13%
    OGN stock has given up its prior gain. Organon sha... Unlock content with Pro Subscription
    1 month ago
    -13.13%
    Organon shares are trading higher after the company beat Q2 estimates and raised FY25 guidance.
    news image

    19 hours ago · accessnewswire.com

    Orogen Royalties and South32 Form Generative Base Metals Alliance

    All dollar figures expressed in United States dollars unless otherwise stated VANCOUVER, BC / ACCESS Newswire / September 4, 2025 / (TSXV:OGN)(OTC:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Compan...

    news image

    2 days ago · businesswire.com

    US Food and Drug Administration (FDA) Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

    SHANGHAI & JERSEY CITY, N.J.--(BUSINESS WIRE)--FDA Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp).

    news image

    1 week ago · accessnewswire.com

    Orogen Royalties Reports Q2 2025 Financial Results Based on Carve-out Financial Statements

    VANCOUVER, BC / ACCESS Newswire / August 26, 2025 / (TSXV:OGN)(OTC:OGNNF) Orogen Royalties Inc. (formerly 1537944 BC Ltd.) ("Orogen" or the "Company") is pleased to announce strong revenue and cash fl...

    news image

    1 week ago · zacks.com

    Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It

    Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.

    news image

    3 weeks ago · seekingalpha.com

    Organon: Valuation Discount Offset By Structural Headwinds

    Organon shares are very cheap, but weak growth, high debt, and a lack of clear catalysts make them a value trap rather than a bargain. Revenue is stagnating as new products only offset legacy declines...

    news image

    3 weeks ago · zacks.com

    Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know

    Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

    news image

    3 weeks ago · zacks.com

    OGN vs. HQY: Which Stock Is the Better Value Option?

    Investors interested in Medical Services stocks are likely familiar with Organon (OGN) and HealthEquity (HQY). But which of these two stocks is more attractive to value investors?

    news image

    4 weeks ago · seekingalpha.com

    Organon Q2 Earnings: It May Be Time To Desert This Sinking Ship (Downgrade)

    Organon & Co.'s shrinking revenues, heavy debt, and slashed dividend make it an unattractive investment despite its low valuation metrics. The Established Brands division is in decline, and new produc...

    news image

    1 month ago · fool.com

    Organon (OGN) Fiscal Q2 Revenue Beats 1%

    Organon (OGN) Fiscal Q2 Revenue Beats 1%

    news image

    1 month ago · seekingalpha.com

    Organon & Co. (OGN) Q2 2025 Earnings Call Transcript

    Organon & Co. (NYSE:OGN ) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Jennifer Halchak - Corporate Participant Juan Camilo Arjona Ferreira - Executive VP, Head of R...

    Add to Watchlist